ライフサイエンスコーパス: poliovirus

1 athogenesis, this treatment had no effect on poliovirus.

2 B3 (CVB3), a picornavirus closely related to poliovirus.

3 e group of mammalian pathogens that includes poliovirus.

4 alytic polio and circulating vaccine-derived poliovirus.

5 nce and secure eradication of all serotype 2 poliovirus.

6 Vaccination has essentially eradicated poliovirus.

7 f the virulent Mahoney strain of wild type 1 poliovirus.

8 major step towards the final eradication of poliovirus.

9 nd dengue virus but not for the nonenveloped poliovirus.

10 serum neutralising antibodies to serotype-3 poliovirus.

11 es required for binding and stabilization of poliovirus.

12 Ac)-containing polysaccharides can stabilize poliovirus.

13 e flavivirus group and not the non-enveloped poliovirus.

14 g global eradication of neurovirulent type-2 polioviruses.

15 uce risks of re-emergence of vaccine-derived polioviruses.

16 strategy used to end the circulation of all polioviruses.

17 eracruz, Mexico, revealed no vaccine-derived polioviruses.

18 ks due to circulating vaccine-derived type 2 polioviruses.

19 art of a crucial strategy for containment of polioviruses.

20 st a large panel of wild and vaccine-derived polioviruses.

21 Using echovirus 7 and poliovirus 1, we confirmed the expression of uORF protei

22 ion certified the eradication of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing par

23 nally, we show that cleavage of eIF4G by the poliovirus 2A protease generates a high-affinity IRES bi

24 Poliovirus 2C(ATPase) has important roles both in RNA re

25 this study, we have searched for residues in poliovirus 2C(ATPase), near a presumed capsid-interactin

26 version and median antibody titres to type 2 poliovirus 4 weeks after vaccination with mIPV2HD or IPV

27 and 99.2% (95.5% to 100.0%) for wild-type 1 poliovirus, 92.5% (79.6% to 98.4%) and 98.7% (95.4% to 9

28 e how different bacteria impact infection of poliovirus, a model enteric virus.

29 ellular protein, GBF1, in the replication of poliovirus, a representative enterovirus.

30 serotype 2, measured by absence of shedding poliovirus after a challenge OPV dose.

31 s on re-introduction or resurgence of type 2 poliovirus after this switch is not understood completel

32 and 93.2% (88.6% to 96.3%) for Sabin 1 and 3 poliovirus alone or in mixtures when tested on 155 stool

33 nt viruses by generating chimeric RdRPs from poliovirus and coxsackievirus B3.

34 licensed vaccines are available only against poliovirus and enterovirus 71, and specific anti-enterov

35 itis virus (EMCV), coxsackievirus B3 (CVB3), poliovirus and enterovirus D68 infection, and chemical i

36 ties in sequencing common samples containing poliovirus and enterovirus mixtures.

37 This work defines the unique interactions of poliovirus and glycans, which provides insight into viri

38 heir association with enterovirus isolation (poliovirus and nonpolio enteroviruses) as an indicator o

39 own that the specificity of encapsidation of poliovirus and of C-cluster coxsackieviruses, which are

40 ities for immunization activities (including poliovirus and other vaccines) and other health benefits

41 The nonstructural protein 3A of poliovirus and related viruses has been shown to directl

42 , a region also involved in CD155 binding to poliovirus and Tactile in human.

43 program will be the complete eradication of poliovirus and the elimination of polio for all time.

44 ing reads also allowed the identification of polioviruses and enteroviruses in artificial mixtures an

45 cine (Sabin), vaccine-derived, and wild-type polioviruses and to ensure an appropriate response.

46 spread of circulating vaccine-derived type 2 polioviruses and vaccine-associated paralytic poliomyeli

47 ) for vaccine and vaccine-derived serotype 2 poliovirus, and 88.3% (81.2% to 93.5%) and 93.2% (88.6%

48 tributes to the emergence of vaccine-derived polioviruses, and counteracts error catastrophe.

49 Enteric viruses, including poliovirus, are spread by the fecal-oral route.

50 d underlying neuropathogenicity has hampered poliovirus-based vector applications.

51 The structures of poliovirus bound to single-domain antibodies presented h

52 Most of the poliovirus burden was shared by 3 major reservoirs: Kara

53 ain short-chain oligosaccharides can bind to poliovirus but do not increase virion stability.

54 such as a six-unit GlcNAc oligomer, can bind poliovirus but fail to enhance virion stability.

55 antibiotic cocktail supported replication of poliovirus but not CVB3.

56 ructurally from canonical Type 1 IRESs (e.g. poliovirus) but nevertheless also contains an essential

57 confirm suppression of hepatitis B virus and poliovirus by ARB.

58 s) to bivalent OPV (containing types 1 and 3 poliovirus) called for intense global communications and

59 Polioviruses can provide a context optimal for generatin

60 e of writing, only 3 countries in which wild poliovirus circulation has never been interrupted remain

61 polio vaccines (OPVs), starting with type 2 poliovirus-containing vaccine and introduction of inacti

62 activated by exposure to heat or bleach, but poliovirus, coxsackievirus B3, and reovirus can be stabi

63 ny important pathogens for humans, including poliovirus, coxsackievirus, rhinovirus, as well as newly

64 We found that, as seen with poliovirus, CVB3 shedding and pathogenesis were reduced

65 elated to type 2-circulating vaccine-derived poliovirus (cVDPV2).

66 n which autophagy constituents are proviral (poliovirus, dengue, and Zika), we developed a panel of k

67 in a subdomain (d10c) that is homologous to poliovirus dIVc.

68 iruses) to bivalent OPV (bOPV; types 1 and 3 polioviruses) during a 2-week period in April 2016.

69 s variants by deep sequencing may aid in the poliovirus endgame and efforts to ensure global polio er

70 e many known and emerging pathogens, such as poliovirus, enteroviruses 71 and D68, and others.

71 d Health Assembly declared the completion of poliovirus eradication a programmatic emergency for glob

72 s quality control agents for the end game of poliovirus eradication are discussed.

73 Global poliovirus eradication efforts include high vaccination

74 Following the declaration of wild-type 2 poliovirus eradication in 2015, the type 2 component was

75 However, poliovirus eradication is hampered globally by epidemics

76 inical studies, and thus may enable complete poliovirus eradication.

77 Non-poliovirus eukaryotic virus abundance (3.68 log(10) vs.

78 n assembly.IMPORTANCE RNA viruses, including poliovirus, evolve rapidly due to the error-prone nature

79 sk for an outbreak of type 2 vaccine-derived poliovirus following virus importation or new emergence.

80 s, such as human rhinovirus, coxsackievirus, poliovirus, foot-and-mouth disease virus, enterovirus D-

81 there have been no cases of serotype 2 wild poliovirus for more than 20 years, transmission of serot

82 e efforts could have contributed to the wild poliovirus-free 2-year period between 24 July 2014 and 1

83 roughout the non-structural coding region of poliovirus from dually transfected cells.

84 Eradication of poliovirus from endemic countries relies on vaccination

85 eic acid sequencing of the VP1 region of the poliovirus genome to determine genetic relatedness among

86 and nucleic acid sequencing of VP1 region of poliovirus genome to determine the genetic relatedness a

87 on is regulated following translation of the poliovirus genome.

88 important addition to our resources against poliovirus given the current epidemiological situation.

89 ainty about whether or not all types of wild polioviruses had been eradicated, but it might increase

90 eria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine; age 6/

91 However, because wild-type 2 poliovirus has been eradicated, the World Health Organiz

92 polio vaccines (OPVs) once all types of wild polioviruses have been eradicated.

93 RNA viruses, such as poliovirus, have a great evolutionary capacity, allowing

94 e barriers to infection.RNA viruses, such as polioviruses, have a great evolutionary capacity and can

95 he replication of certain viruses, including poliovirus, herpes simplex virus (HSV), cytomegalovirus

96 o protect against paralysis caused by type 2 poliovirus; however, this inclusion will not prevent tra

97 from Jan 1, 1980, to Nov 1, 2018, comparing poliovirus immunisation schedules in a primary series.

98 of poliomyelitis associated with wild-type 1 poliovirus in districts of Pakistan over 6-month interva

99 ns of circulating serotype 2 vaccine-derived poliovirus in northern Nigeria (Borno and Sokoto states)

100 n (Balochistan Province) and serotype 1 wild poliovirus in Pakistan, Afghanistan, and Nigeria (Borno)

101 myelitis certified the eradication of type 2 poliovirus in September 2015, making type 2 poliovirus t

102 dentified environmental surveillance (ES) of poliovirus in the poliomyelitis eradication strategic pl

103 was able to distinguish complex mixtures of polioviruses in environmental samples.

104 or the detection and real-time sequencing of polioviruses in stool and environmental samples.

105 sensitive direct detection and sequencing of polioviruses in stool and environmental samples.

106 th monopartite members of the order, such as poliovirus, indicated that packaging is linked to replic

107 more sensitive to antibiotic treatment than poliovirus, indicating that closely related viruses may

108 Estimated movement of poliovirus-infected individuals was associated with the

109 Because the model recapitulates human poliovirus infection and poliomyelitis, it can be used t

110 Because the model recapitulates human poliovirus infection and poliomyelitis, it can be used t

111 Here we show that poliovirus infection in immune-competent mice requires a

112 Here, the authors show that poliovirus infection in mice requires adaptation to inna

113 ccines.IMPORTANCE Early pathogenic events of poliovirus infection remain largely undefined, and there

114 the early pathogenic events in natural oral poliovirus infection remain poorly defined.

115 to decrease coxsackievirus infection, while poliovirus infection was unaffected.

116 When poliovirus infects a cell, it undergoes a change in its

117 hared by the new compounds and already-known poliovirus inhibitors.

118 PCBP2 has three KH domains and binds poliovirus IRES domain dIV in the vicinity of the tetral

119 Environmental surveillance (ES) for poliovirus is increasingly important for polio eradicati

120 ating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free worl

121 imized whole-genome sequencing protocols for poliovirus isolates and FTA cards using next-generation

122 Poliovirus isolates were grouped into 11 distinct cluste

123 Poliovirus isolates were grouped into eleven distinct cl

124 plementary technical and support capacities (poliovirus isolation, molecular strain characterization

125 After 2 years without reporting any wild poliovirus (July 2014-2016), the region undertook the sy

126 de insights into several other stages of the poliovirus life cycle, including the mechanism of recept

127 deficiencies who can excrete vaccine-derived poliovirus long-term.

128 ngineer additional polymerase mutations into poliovirus (M392A, M392L, M392V, K375R, and R376K).

129 ng method demonstrated reliable detection of poliovirus mutations at levels of <1%, depending on read

130 Type 2 poliovirus neutralising antibodies were measured at days

131 Poliovirus neutralizing antibodies were measured in sera

132 ample per child was analyzed for presence of poliovirus neutralizing antibodies.

133 before and after vaccinations was tested for poliovirus-neutralizing antibodies.

134 uses, we tested novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are geneticall

135 The risk of transmission of type 2 poliovirus or Sabin 2 virus on re-introduction or resurg

136 capsid protein(s) and replication proteins (poliovirus), or (b) by the high affinity interaction of

137 During the poliovirus outbreak in Cameroon from October 2013 to Apr

138 By studying the emergence of vaccine-derived poliovirus outbreaks, Stern et al. describe how a combin

139 tire viral genome" play the critical role in poliovirus packaging specificity.

140 ning viremia), extending previous studies of poliovirus pathogenesis in humans.

141 supplementing historical reconstructions of poliovirus pathogenesis.

142 er identify a region in the multi-functional poliovirus protein 2B as a hotspot for the accumulation

143 chimeras supported the growth of infectious poliovirus, providing insights into enterovirus species-

144 71 and several EV-B species members, but not poliovirus (PV) (EV-C species).

145 fashion and also blocked the replication of poliovirus (PV) and foot-and-mouth disease virus (FMDV)

146 , and the positive-sense single-stranded RNA poliovirus (PV) and human rhinovirus C (HRV-C).

147 d increases the rate of restructuring of the poliovirus (PV) IRES.

148 The poliovirus (PV) is currently targeted for worldwide erad

149 Poliovirus (PV) is the causative agent of poliomyelitis,

150 stability, we identified and characterized a poliovirus (PV) mutant with increased resistance to heat

151 tations within the capsid-coding sequence of poliovirus (PV) that were established in the population

152 Poliovirus (PV), a prototype for human pathogenic positi

153 The model enterovirus is poliovirus (PV), the causative agent of poliomyelitis, a

154 tis is a highly infectious disease caused by poliovirus (PV).

155 ntrary to what has been proposed previously, poliovirus RdRp that was bound to RNA with an incorporat

156 Here, we have used (31)P NMR with poliovirus RdRp to show that the binding environment of

157 y and RdRp-RNA-NTP ternary complexes for the poliovirus RdRp, including an open-to-closed conformatio

158 ne response in mice transgenic for the human poliovirus receptor.

159 71 based upon previously reported assays for poliovirus recombination.

160 eatment of mice prior to oral infection with poliovirus reduced viral replication and pathogenesis.

161 Protection against poliovirus remained elevated 6 and 11 months after an IP

162 trates that early in the infectious process, poliovirus replication occurs in both epithelial cells (

163 trates that early in the infectious process, poliovirus replication occurs in both epithelial cells (

164 which determinants are important to support poliovirus replication.

165 The eradication of wild and vaccine-derived poliovirus requires the global withdrawal of oral poliov

166 We found that DNase treatment of poliovirus RNA followed by random reverse transcription

167 the apical region of stem-loop IV (SLIVm) of poliovirus RNA in its full-length and truncated form.

168 by exploiting well-defined mutations in the poliovirus RNA-dependent RNA polymerase (RDRP), namely,

169 ng them, 7 and 11 were highly active against poliovirus Sabin 1-3.

170 ing of our in-house chemical library against poliovirus Sabin strains led to the identification of co

171 We assessed seroconversion against poliovirus serotypes 1, 2, and 3, and intestinal immunit

172 ation of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the b

173 e dose of IPV (groups A and B) for all three poliovirus serotypes: the type 1 response comprised 212

174 Assembly (WHA) resolved in 1988 to eradicate poliovirus, several rounds of immunization campaigns hav

175 bin types and also exhibited higher rates of poliovirus shedding (p = 0.020).

176 Poliovirus shedding 7 days after challenge was less prev

177 g and pathogenesis while having no effect on poliovirus shedding and pathogenesis.

178 The primary outcome was poliovirus shedding in stool 7 days after bivalent OPV c

179 Vaccine poliovirus shedding stopped at a median of 23 days (IQR

180 s (p = 0.016) were inversely associated with poliovirus shedding.

181 tion between eukaryotic virome abundance and poliovirus shedding.

182 ose that population genetic dynamics enables poliovirus spread between tissues through optimization o

183 OPV protects from disease and limits poliovirus spread.

184 found that bacterial polysaccharides enhance poliovirus stability against heat or bleach inactivation

185 Phylogenetic analysis suggests that wild poliovirus strains from endemic regions were genetically

186 Our analysis also indicates that circulating poliovirus strains in unimmunized populations serve as a

187 Global poliovirus surveillance involves virus isolation from st

188 om FTA cards will aid in facilitating global poliovirus surveillance.

189 ss stabilized virus-like particles of type 3 poliovirus that can induce a protective immune response

190 ral particle stability, we isolated a mutant poliovirus that is heat resistant.

191 poliovirus in September 2015, making type 2 poliovirus the first human pathogen to be eradicated sin

192 The eradication of type 2 poliovirus, the absence of detection of type 3 polioviru

193 ient individuals who excrete vaccine-derived polioviruses threaten polio eradication.

194 The emergence of circulating vaccine-derived polioviruses through evolution of the oral polio vaccine

195 bivalent OPV (bOPV; containing types 1 and 3 poliovirus), thus withdrawing OPV2.

196 that viral RNA recombination is required for poliovirus to evade ribavirin-induced error catastrophe.

197 strophe, we selected for ribavirin-resistant poliovirus to identify polymerase residues that facilita

198 de since November 2012, and cornering type 1 poliovirus to only a few geographic areas of 3 countries

199 lent OPV (tOPV; containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 an

200 trivalent OPV (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containing types 1 and 3 po

201 from trivalent OPV (tOPV; types 1, 2, and 3 polioviruses) to bivalent OPV (bOPV; types 1 and 3 polio

202 ors and movement patterns that contribute to poliovirus transmission across Pakistan would support ev

203 ed subpopulations, using an existing dynamic poliovirus transmission and oral poliovirus vaccine evol

204 enges in eradicating polio due to widespread poliovirus transmission and security challenges.

205 Even though poliovirus transmission has not yet been stopped globall

206 oratory investigations provide insights into poliovirus transmission patterns and genomic diversity t

207 oratory investigations provide insights into poliovirus transmission patterns and genomic diversity t

208 also investigated with a dynamical model of poliovirus transmission to observe prevalence and incide

209 et mop-up campaigns in such areas to contain poliovirus transmission.

210 intensive target mop-up campaigns to contain poliovirus transmission.

211 mical synthesis generated viable variants of poliovirus type 1 (PV1), whose ORF (6,189 nucleotides) c

212 kistan is among 3 countries endemic for wild poliovirus type 1 (WPV1) circulation that are still stru

213 lio antibodies was 100% in all districts for poliovirus type 1 and poliovirus type 3; it ranged betwe

214 adults were challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently treat

215 us type 3; it ranged between 90% and 93% for poliovirus type 2 (PV2) in children who received 1 full

216 ne and withdrawal of oral vaccine containing poliovirus type 2 (PV2), a PV2-containing vaccine was no

217 substantial/enhanced immunogenicity against poliovirus type 2 after 1 to 2 doses of IPV respectively

218 n in selected areas at risk for emergence of poliovirus type 2 during the next phase of the polio era

219 of a novel monovalent high-dose inactivated poliovirus type 2 vaccine (mIPV2HD) in infants.

220 Here, we report the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetic

221 % in all districts for poliovirus type 1 and poliovirus type 3; it ranged between 90% and 93% for pol

222 The poliovirus type I IRES is able to recruit ribosomal mach

223 Seroconversion to each poliovirus type was seen in 100% of rats that received 1

224 emonstrated excellent immunogenicity against poliovirus types 1 and 3, and substantial/enhanced immun

225 Seroconversion rates for poliovirus types 1 and 3, respectively, were 98.9% (95%C

226 The primary outcome was vaccine response to poliovirus types 1, 2, and 3 at age 22 weeks (routine im

227 s were tested for neutralizing antibodies to poliovirus types 1, 2, and 3 in 580 younger and 297 olde

228 g the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was already high for the th

229 The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with titres more than or eq

230 of fIPV recipients had an immune response to poliovirus types 1, 2, and 3, respectively, compared wit

231 d for presence of neutralizing antibodies to poliovirus types 1, 2, and 3.

232 provides molecular epidemiological data from polioviruses used to inform programmatic and immunizatio

233 ring viral RNA abundance, we also found that poliovirus utilizes these autophagy components for intra

234 Intradermal (id) fractional inactivated poliovirus vaccine ([fIPV] one fifth of normal IPV dose)

235 A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intraderma

236 ractional-dose administration of inactivated poliovirus vaccine (fIPV) could increase IPV affordabili

237 mal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative

238 0.1 mL) intradermal doses of the inactivated poliovirus vaccine (ID fIPV) is positively correlated wi

239 aptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the

240 In 2014, 2 studies showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in c

241 a vaccine (IIV3) or a control of inactivated poliovirus vaccine (IPV) in the beginning of the study;

242 phase 4 study and either OPV or inactivated poliovirus vaccine (IPV) in the novel OPV2 phase 2 study

243 replaced 1 intramuscular dose of inactivated poliovirus vaccine (IPV) with 2 doses of intradermal fra

244 Monovalent type 2 oral poliovirus vaccine (mOPV2) stockpile is low.

245 The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in

246 ber of newborns given the first dose of oral poliovirus vaccine (OPV) according to the RI schedule an

247 del expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV2) ce

248 ts/caregivers if the child received any oral poliovirus vaccine (OPV) in Myanmar and, for younger chi

249 Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries required

250 Oral poliovirus vaccine (OPV) is less immunogenic in low- or

251 me in affecting immune responses to the oral poliovirus vaccine (OPV) is unknown.

252 irus vaccine in all 126 countries using oral poliovirus vaccine (OPV) only as of 2012, (2) full withd

253 cularly, among adults with a history of oral poliovirus vaccine (OPV) receipt.

254 a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be repl

255 fferent interventions were assessed for oral poliovirus vaccine (OPV), oral rotavirus vaccine (RVV),

256 Early trials suggested that oral poliovirus vaccine (OPV), when administered concomitantl

257 y in children previously immunized with oral poliovirus vaccine (OPV).

258 enteric viruses, potentially including oral poliovirus vaccine (OPV).

259 Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 and

260 thdrawal of the serotype 2 component of oral poliovirus vaccine (OPV2) was implemented in April 2016

261 d regulatory approval for use of inactivated poliovirus vaccine and bivalent OPV in routine immunizat

262 ces in approach observed between inactivated poliovirus vaccine and bivalent OPV.

263 Due to global shortage of inactivated poliovirus vaccine and withdrawal of oral vaccine contai

264 ion (0.66; .44-1.00) when censoring for oral poliovirus vaccine campaigns.

265 fied an analysis censoring follow-up at oral poliovirus vaccine campaigns.

266 Oral poliovirus vaccine can mutate to regain neurovirulence.

267 ing dynamic poliovirus transmission and oral poliovirus vaccine evolution model.

268 or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).

269 ssess whether antibiotics would improve oral poliovirus vaccine immunogenicity.

270 arned during the introduction of inactivated poliovirus vaccine in 3 countries that would make future

271 (1) introduction of >/=1 dose of inactivated poliovirus vaccine in all 126 countries using oral polio

272 eived the third dose of pentavalent and oral poliovirus vaccine, respectively, but only 65% received

273 ype 2 component, introduction of inactivated poliovirus vaccine, strengthening of routine immunizatio

274 dule of ages 6 and 10 weeks, along with oral poliovirus vaccine.

275 ntually need to be replaced with inactivated poliovirus vaccines (IPV).

276 ines (OPVs) and replacement with inactivated poliovirus vaccines (IPVs).

277 virus requires the global withdrawal of oral poliovirus vaccines (OPVs) and replacement with inactiva

278 ated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated development of

279 synthesize stable VLPs as future genome-free poliovirus vaccines.

280 est that monitoring emerging vaccine-related poliovirus variants by deep sequencing may aid in the po

281 No vaccine-derived poliovirus variants were detected.

282 nomic region to characterize vaccine-related poliovirus variants.

283 ttention has been devoted to vaccine-derived poliovirus (VDPV) surveillance due to its severe consequ

284 PVs, especially for those in vaccine-derived polioviruses (VDPV), circulating VDPV, or immunodeficien

285 , transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic cases in sev

286 The emergence of vaccine-derived polioviruses (VDPVs), however, remains a risk, as oral p

287 ed circulation of serotype 2 vaccine-derived polioviruses (VDPVs).

288 igate this, we infer a fitness model for the poliovirus viral protein 1 (vp1), which successfully pre

289 ria or bacterial surface glycans can enhance poliovirus virion stability and limit inactivation from

290 cryo-electron microscopy, expanded 80S-like poliovirus virions (poliovirions) were visualized in com

291 Poliovirus virions are nonenveloped icosahedral 30-nm pa

292 Most burden of poliovirus was shared by three major reservoirs i.e. Kar

293 ing the risk of outbreaks of vaccine-derived polioviruses, we tested novel monovalent oral type-2 pol

294 c analysis showed that EVs of the C species (polioviruses) were associated with the post-polio syndro

295 extracted from cecal contents of mice, bound poliovirus, with each bacterium binding multiple virions

296 liovirus, the absence of detection of type 3 poliovirus worldwide since November 2012, and cornering

297 e monitoring paid off, as the number of wild poliovirus (WPV) cases detected in Nigeria were reduced

298 Despite a 99% reduction in annual wild poliovirus (WPV) cases since 1988, tackling the last 1%

299 countries that had already interrupted wild poliovirus (WPV) transmission, compared with findings fo

300 an is among three countries endemic for wild poliovirus (WPV1) circulation, still struggling for erad